Paradoxical Expression of R-10G-reactive Antigen in Human Testicular Embryonal Carcinoma.
Akifumi MuramotoSo InamuraHitomi HoshinoNaoki TeradaMotohiro KobayashiPublished in: The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society (2023)
Thus far, several monoclonal antibodies directed against cell-surface carbohydrate antigens have been generated. Among them, R-10G reportedly reacts selectively with human embryonic stem and induced pluripotent stem cells, but not with embryonal carcinoma (EC) cells. However, EC cells derived from patients' EC tumors may exhibit varying levels of R-10G-reactive antigen expression. Thus, we asked whether human EC tissues or germ cell tumor (GCT) tissues other than EC express R-10G-reactive antigen. To do so, we quantitatively analyzed R-10G-reactive antigen expression in 83 testicular GCT surgical specimens containing a total of 125 various GCT components. Accordingly, in all EC components examined, the EC cell plasma membrane was immunolabeled with R-10G, while most seminoma components were R-10G-negative. In non-seminomatous GCT (NSGCT) other than EC (non-EC NSGCT), R-10G-reactive antigen expression was variable, but signal distribution was focal, and the average intensity was weaker than that seen in EC. The percentages of R-10G-positive cells in these three groups varied with high statistical significance ( p <0.001 for all combinations). These findings indicate that the R-10G-reactive antigen is preferentially expressed in human testicular EC tissues and, thus, could be used as a diagnostic marker for this malignancy.
Keyphrases
- germ cell
- induced pluripotent stem cells
- endothelial cells
- poor prognosis
- induced apoptosis
- cell cycle arrest
- gene expression
- pluripotent stem cells
- end stage renal disease
- single cell
- ejection fraction
- signaling pathway
- endoplasmic reticulum stress
- stem cells
- cell surface
- oxidative stress
- chronic kidney disease
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- high intensity
- bone marrow
- cell therapy
- patient reported outcomes